Erratum to ‘Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma’ (European Journal of Cancer (2019) 108 (33–40), (S0959804918315399), (10.1016/j.ejca.2018.11.031))

The publisher regrets the conflict of interest information provided by the authors was not included in the paper and instead the incorrect statement ‘None declared’ was published. The publisher would like to apologise for any inconvenience caused. Please see below the statement provided by the authors: G.D.V. declared consultancy or advisory role for Janssen, Pfizer, Novartis, Bayer and Astellas–Medivation and funding from Ipsen. P.Ba. declared consultancy or advisory role for Pfizer, Novartis, Ipsen, Bristol-Myers Squibb (BMS), Roche, Merck, and Janssen. G.M. declared consultancy or advisory role for Pfizer, Novartis, Ipsen, BMS and Janssen. Y.-A.V. declared receiving honoraria and consulting or advisory role for Pfizer, Novartis, BMS, Ipsen, Roche, Astellas, Janssen and Sanofi. M.G.-G. declared receiving travel fee from PFIZER, BMS and Novartis. L.M. declared receiving honoraria from Sanofi, Astellas, Janssen, Pfizer, Ipsen and BMS. F.R. declared consulting or advisory role for Novartis, Pfizer, BMS, Janssen and Ipsen. B.E. declared receiving honoraria and consulting or advisory role for Bayer, Novartis, Pfizer, Exelixis, BMS, Ipsen, EUSA Pharma, Roche and Genentech. L.A. declared consulting or advisory role for Novartis, Pfizer, Amgen, BMS, Ipsen, Roche, Astellas and Merck. M.A., E.A., P.Bo., T.P., G.G. and F.P. declared no conflict of interest.